CStone Pharmaceuticals reports CS2009 Phase I safety; Grade ≥3 TRAEs rise to 23%

Reuters03-26 17:01

<a href="https://laohu8.com/S/02616">CStone Pharmaceuticals</a> reports CS2009 Phase I safety; Grade ≥3 TRAEs rise to 23%

CStone reported updated Phase I/II clinical progress for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, from ongoing trials in Australia and China.
As of mid-March 2026, Phase I enrolled 113 patients with advanced solid tumors and reported a 23% incidence of Grade ≥3 treatment-related adverse events.
In Phase II first-line NSCLC with PD-L1 TPS ≥50%, CS2009 monotherapy showed a 90% overall response rate and a 100% disease control rate.
The company said updated Phase I and Phase II data are expected to be presented at the 2026 ASCO Annual Meeting and/or the 2026 ESMO Congress.
CStone plans to initiate Phase III global multi-regional clinical trials for CS2009 by the end of 2026 in indications including NSCLC and colorectal cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068888), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622307678?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 17:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622307678","market":"fut","top_or_hot":-1,"title":"CStone Pharmaceuticals reports CS2009 Phase I safety; Grade ≥3 TRAEs rise to 23%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/02616\">CStone Pharmaceuticals</a> reports CS2009 Phase I safety; Grade ≥3 TRAEs rise to 23%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          CStone reported updated Phase I/II clinical progress for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, from ongoing trials in Australia and China.\n        </li>\n<li>\n          As of mid-March 2026, Phase I enrolled 113 patients with advanced solid tumors and reported a 23% incidence of Grade ≥3 treatment-related adverse events.\n        </li>\n<li>\n          In Phase II first-line NSCLC with PD-L1 TPS ≥50%, CS2009 monotherapy showed a 90% overall response rate and a 100% disease control rate.\n        </li>\n<li>\n          The company said updated Phase I and Phase II data are expected to be presented at the 2026 ASCO Annual Meeting and/or the 2026 ESMO Congress.\n        </li>\n<li>\n          CStone plans to initiate Phase III global multi-regional clinical trials for CS2009 by the end of 2026 in indications including NSCLC and colorectal cancer.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068888), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharmaceuticals reports CS2009 Phase I safety; Grade ≥3 TRAEs rise to 23%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharmaceuticals reports CS2009 Phase I safety; Grade ≥3 TRAEs rise to 23%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 17:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/02616\">CStone Pharmaceuticals</a> reports CS2009 Phase I safety; Grade ≥3 TRAEs rise to 23%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          CStone reported updated Phase I/II clinical progress for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, from ongoing trials in Australia and China.\n        </li>\n<li>\n          As of mid-March 2026, Phase I enrolled 113 patients with advanced solid tumors and reported a 23% incidence of Grade ≥3 treatment-related adverse events.\n        </li>\n<li>\n          In Phase II first-line NSCLC with PD-L1 TPS ≥50%, CS2009 monotherapy showed a 90% overall response rate and a 100% disease control rate.\n        </li>\n<li>\n          The company said updated Phase I and Phase II data are expected to be presented at the 2026 ASCO Annual Meeting and/or the 2026 ESMO Congress.\n        </li>\n<li>\n          CStone plans to initiate Phase III global multi-regional clinical trials for CS2009 by the end of 2026 in indications including NSCLC and colorectal cancer.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068888), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL70Wbzt:1","article_id":"2622307678","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622307678","pubTimestamp":1774515690,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CStone reported updated Phase I/II clinical progress for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, from ongoing trials in Australia and China.As of mid-March 2026, Phase I enrolled 113 patients with advanced solid tumors and reported a 23% incidence of Grade ≥3 treatment-related adverse events.In Phase II first-line NSCLC with PD-L1 TPS ≥50%, CS2009 monotherapy showed a 90% overall response rate and a 100% disease control rate.The company said updated Phase I and Phase II data are expected to be presented at the 2026 ASCO Annual Meeting and/or the 2026 ESMO Congress.CStone plans to initiate Phase III global multi-regional clinical trials for CS2009 by the end of 2026 in indications including NSCLC and colorectal cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","02616":"基石药业-B","BK1161":"生物科技"},"translate_title":"基石药业报告CS2009 I期安全性；≥3级TRAE上升至23%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":0.9},"content_text":"CStone Pharmaceuticals reports CS2009 Phase I safety; Grade ≥3 TRAEs rise to 23%\n    \n\n\n          CStone reported updated Phase I/II clinical progress for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, from ongoing trials in Australia and China.\n        \n\n          As of mid-March 2026, Phase I enrolled 113 patients with advanced solid tumors and reported a 23% incidence of Grade ≥3 treatment-related adverse events.\n        \n\n          In Phase II first-line NSCLC with PD-L1 TPS ≥50%, CS2009 monotherapy showed a 90% overall response rate and a 100% disease control rate.\n        \n\n          The company said updated Phase I and Phase II data are expected to be presented at the 2026 ASCO Annual Meeting and/or the 2026 ESMO Congress.\n        \n\n          CStone plans to initiate Phase III global multi-regional clinical trials for CS2009 by the end of 2026 in indications including NSCLC and colorectal cancer.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068888), on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622307678","isCrawlerRequest":true}